BiotechTube
Home/Oxford Cancer Biomarkers/David Kerr
DK

David Kerr

Co-Founder

Oxford Cancer Biomarkers

Therapeutic Areas

OncologyColorectal Cancer

Oxford Cancer Biomarkers Pipeline

DrugIndicationPhase
ToxNav®Prediction of toxicity to 5-FU/capecitabine chemotherapyCommercial
OncoProgPrognostic risk stratification for colorectal cancer relapseApproved

Leadership Team at Oxford Cancer Biomarkers

NL
Nick La Thangue
Co-Founder
KX
Kevin Xu
Director of Computational Pathology
View full Oxford Cancer Biomarkers profile